This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/7/2025
Tom
President & Chief Operating Officer
as well so absolutely I think you should be thinking about two main factors you know new patient starts and active patients because it's going to be the active patients that we believe that we can continue to grow over time that are really going to be meaningful for the ongoing revenue uptick for this brand into the long term
Catherine Owen-Adams
Chief Financial Officer
Liz, do you want to touch on our positioning versus the new Celina product? Sure.
Liz
Chief Medical Officer
I'll start out with the fact that, I mean, we're delighted for the PWS community that there is now a first therapy available for them. That said, I think we see this as an area of significant high unmet need and complex patients who are dealing with a number of different challenges. It's the kind of space where we think that it's likely that there is going to be absolutely room for multiple agents that are used with different MOAs, with different benefit-risk profiles that physicians can use according to the patient that's in front of them. I don't know if there's anything you want to add here, Tom?
You're reading a preview of the ACAD Q1 2025 earnings call.
Free account.
Disclaimer